{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:40:00Z","timestamp":1793328000367,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.phrs.2024.107060","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T11:58:16Z","timestamp":1704455896000},"page":"107060","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"200","author":[{"given":"Qi-An","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Hao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Xiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Li","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Bo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.phrs.2024.107060_bib1","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1158\/2159-8290.CD-20-1616","article-title":"Mechanisms of resistance to KRAS(G12C)-targeted therapy","volume":"11","author":"Akhave","year":"2021","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.phrs.2024.107060_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.phrs.2024.107060_bib3","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.cell.2007.05.018","article-title":"GEFs and GAPs: critical elements in the control of small G proteins","volume":"129","author":"Bos","year":"2007","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.phrs.2024.107060_bib4","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/nrc2109","article-title":"Hyperactive Ras in developmental disorders and cancer","volume":"7","author":"Schubbert","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"14","key":"10.1016\/j.phrs.2024.107060_bib5","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.phrs.2024.107060_bib6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.phrs.2024.107060_bib7","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2024.107060_bib8","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Network, Comprehensive molecular characterization of human colon and rectal cancer, Nature 487(7407), 2012, pp. 330\u2013337.","DOI":"10.1038\/nature11252"},{"issue":"2","key":"10.1016\/j.phrs.2024.107060_bib9","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1097\/JTO.0000000000000438","article-title":"KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma","volume":"10","author":"Nadal","year":"2015","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.phrs.2024.107060_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100567","article-title":"Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)","volume":"7","author":"Ciardiello","year":"2022","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.phrs.2024.107060_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/jnci\/djr523","article-title":"Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome","volume":"104","author":"Ihle","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"issue":"12","key":"10.1016\/j.phrs.2024.107060_bib12","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1038\/s41416-018-0322-4","article-title":"A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K\/MTOR inhibitor voxtalisib in patients with advanced solid tumours","volume":"119","author":"Schram","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2024.107060_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ccr.2010.05.025","article-title":"A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma","volume":"18","author":"Puyol","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2024.107060_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2019.06.007","article-title":"Drugging K-Ras(G12C) through covalent inhibitors: Mission possible?","volume":"202","author":"Ni","year":"2019","journal-title":"Pharm. Ther."},{"issue":"11","key":"10.1016\/j.phrs.2024.107060_bib15","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s41571-018-0105-0","article-title":"Therapeutic strategies to target RAS-mutant cancers","volume":"15","author":"Ryan","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"7477","key":"10.1016\/j.phrs.2024.107060_bib16","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","article-title":"K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions","volume":"503","author":"Ostrem","year":"2013","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.phrs.2024.107060_bib17","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.phrs.2024.107060_bib18","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRAS(G12C) mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.phrs.2024.107060_bib19","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","article-title":"The current state of the art and future trends in RAS-targeted cancer therapies","volume":"19","author":"Punekar","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2024.107060_bib20","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.cell.2020.09.044","article-title":"Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients","volume":"183","author":"Kim","year":"2020","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.phrs.2024.107060_bib21","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.annonc.2021.06.001","article-title":"Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches","volume":"32","author":"Reck","year":"2021","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2024.107060_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100745","article-title":"Targeting KRAS(G12C) in colorectal cancer: the beginning of a new era","volume":"8","author":"Ciardiello","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.phrs.2024.107060_bib23","doi-asserted-by":"crossref","first-page":"S826","DOI":"10.1016\/j.annonc.2020.08.1593","article-title":"1279P Impact of KRAS mutations and subtypes on efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC)","volume":"31","author":"Mazieres","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2024.107060_bib24","article-title":"LBA4 Preliminary safety and efficacy of adagrasib with pembrolizumab in treatment-na\u00efve patients with advanced non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation","volume":"16","author":"J\u00e4nne","year":"2022","journal-title":"Immuno-Oncol. Technol."},{"issue":"9, Supplement","key":"10.1016\/j.phrs.2024.107060_bib25","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jtho.2022.07.025","article-title":"OA03.06 CodeBreaK 100\/101: First Report of Safety\/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC","volume":"17","author":"Li","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"8","key":"10.1016\/j.phrs.2024.107060_bib26","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1158\/2159-8290.CD-20-0187","article-title":"EGFR Blockade Reverts Resistance to KRAS(G12C) Inhibition in Colorectal Cancer","volume":"10","author":"Amodio","year":"2020","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.phrs.2024.107060_bib27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.phrs.2024.107060_bib28","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1158\/1078-0432.CCR-17-3416","article-title":"Clinical and pathological characteristics of KEAP1- and NFE2L2-mutated non-small cell lung carcinoma (NSCLC)","volume":"24","author":"Frank","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.phrs.2024.107060_bib29","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1158\/1078-0432.CCR-16-2410","article-title":"LKB1 expression correlates with increased survival in patients with advanced non-small cell lung cancer treated with chemotherapy and bevacizumab","volume":"23","author":"Bonanno","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2024.107060_bib30","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/1078-0432.CCR-17-1841","article-title":"Effects of co-occurring genomic alterations on outcomes in patients with KRAS-mutant non-small cell lung cancer","volume":"24","author":"Arbour","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2024.107060_bib31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.lungcan.2019.05.002","article-title":"Impact of KEAP1\/NFE2L2\/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer","volume":"134","author":"Hellyer","year":"2019","journal-title":"Lung Cancer (Amst. Neth.)"},{"issue":"3","key":"10.1016\/j.phrs.2024.107060_bib32","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jtho.2021.10.013","article-title":"Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status","volume":"17","author":"Ricciuti","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.phrs.2024.107060_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003027","article-title":"Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial","volume":"10","author":"West","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2024.107060_bib34","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-19-1167","article-title":"The KRAS(G12C) inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients","volume":"10","author":"Hallin","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.phrs.2024.107060_bib35","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-22-1420","article-title":"Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC","author":"Negrao","year":"2023","journal-title":"Cancer Discov."},{"issue":"16_suppl","key":"10.1016\/j.phrs.2024.107060_bib36","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.9008","article-title":"Biomarker subgroup analyses of CodeBreaK 200, a phase 3 trial of sotorasib versus (vs) docetaxel in patients (pts) with pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC)","volume":"41","author":"Skoulidis","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.phrs.2024.107060_bib37","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS9129","article-title":"KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRASG12C mutation","volume":"39","author":"Mok","year":"2021","journal-title":"J. Clin. Oncol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824000045?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661824000045?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:47:26Z","timestamp":1760914046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661824000045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":37,"alternative-id":["S1043661824000045"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107060","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes following KRASG12C inhibitor treatment in patients with KRASG12C-mutated solid tumors: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2024.107060","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107060"}}